Drugs / 177Lu-TLX591
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06520345 | Jul 2024 → Dec 2027 expected | prostate carcinoma | Telix Pharmaceuticals (Innovations) Pty Limited | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-TLX591 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06520345 ↗ |